Results from Breast Cancer Index testing prompted more than 40% of physicians to change extended endocrine therapy decisions for women with early-stage, hormone receptor-positive breast cancer.An ...
For Ashliann Mazeika, a diagnosis at 24 led to a decade-long treatment journey affirmed by the Breast Cancer Index test. For Ashliann Mazeika, a diagnosis of early-stage breast cancer at the age of 24 ...
Final analysis of 3,000-patient study shows Breast Cancer Index testing supports high rates of change in physician treatment recommendations related to extended endocrine therapy Publication coincides ...
Findings from 11 investigational studies include new data in premenopausal women and comparative analyses of BCI Testing to the 21-gene assay “These data reinforce Hologic’s continued commitment to ...
The Breast Cancer Index (BCI) can predict which premenopausal women with hormone receptor–positive breast cancer benefit from ovarian function suppression (OFS) therapy. Women with BCI HOXB13/IL17BR ...
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness. Findings from 11 investigational studies include new ...
MARLBOROUGH, Mass., September 24, 2026--(BUSINESS WIRE)--Hologic, Inc. and its subsidiary, Biotheranostics, Inc., today announced newly published data in JAMA Network Open showing that Breast Cancer ...
The findings come from a large-scale BCI Registry Study conducted across multiple institutions at the Sarah Cannon Research Institute, involving nearly 3,000 patients with early-stage, hormone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results